Pacritinib - CTI BioPharma

Drug Profile

Pacritinib - CTI BioPharma

Alternative Names: ENPAXIQ; ONX-0803; Pacritinibum; SB-1518

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator S*BIO
  • Developer Cardiff University; CTI BioPharma; National Cancer Research Institute; Ohio State University Comprehensive Cancer Center; S*BIO; University of California, San Diego; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine; Weill Cornell Medical College
  • Class Antineoplastics; Macrocyclic compounds; Polycyclic bridged compounds; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Interleukin-1 receptor-associated kinase inhibitors; Janus kinase-2 inhibitors; Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myeloproliferative disorders; Myelofibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Myelofibrosis
  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders; Thrombocytopenia
  • Phase I/II Graft-versus-host disease
  • Phase I Haematological disorders
  • Preclinical Chronic myeloid leukaemia
  • Suspended Colorectal cancer
  • Discontinued Lymphoma

Most Recent Events

  • 01 Nov 2018 CTI BioPharma plans a Type C meeting with the US FDA to discuss the design of a phase III trial in myelofibrosis patients with severe thrombocytopenia
  • 02 Aug 2018 An Independent Data Monitoring Committee expects to conduct a second interim analysis of the phase II PAC203 trial in Myelofibrosis in the third quarter of 2018
  • 02 Aug 2018 CTI Biopharma plans to meet with US FDA for discussions related to second interim analysis of the phase II PAC203 trial in Myelofibrosis in the fourth quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top